newdrugapprovals.org
Caplacizumab-yhdp, カプラシズマブ
FDA approves first therapy Cablivi (caplacizumab-yhdp) カプラシズマブ , for the treatment of adult patients with a rare blood clotting disorder FDA February 6, 2019 Release The U.S. Food and Drug Adminis…